RAKYNVIS Trademark

Trademark Overview

On Thursday, March 11, 2021, a trademark application was filed for RAKYNVIS with the United States Patent and Trademark Office. The USPTO has given the RAKYNVIS trademark a serial number of 90573925. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Friday, July 5, 2024. This trademark is owned by Coherus BioSciences, Inc.. The RAKYNVIS trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations for the treatment of oncological diseases and disorders
rakynvis

General Information

Serial Number90573925
Word MarkRAKYNVIS
Filing DateThursday, March 11, 2021
Status734 - FIFTH EXTENSION - GRANTED
Status DateFriday, July 5, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 9, 2021

Trademark Statements

Goods and Servicespharmaceutical preparations for the treatment of oncological diseases and disorders
Translation of Words in MarkThe wording "RAKYNVIS" has no meaning in a foreign language.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, June 11, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCoherus BioSciences, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressRedwood City, CA 94065
Party NameCoherus BioSciences, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressRedwood City, CA 94065

Trademark Events

Event DateEvent Description
Friday, June 11, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, March 15, 2021NEW APPLICATION ENTERED
Monday, August 16, 2021ASSIGNED TO EXAMINER
Monday, August 16, 2021NON-FINAL ACTION WRITTEN
Monday, August 16, 2021NON-FINAL ACTION E-MAILED
Monday, August 16, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, September 24, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, September 24, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, September 24, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, October 5, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 20, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 9, 2021PUBLISHED FOR OPPOSITION
Tuesday, November 9, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 4, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 28, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, June 28, 2022SOU EXTENSION 1 FILED
Tuesday, June 28, 2022SOU EXTENSION 1 GRANTED
Thursday, June 30, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 29, 2022SOU TEAS EXTENSION RECEIVED
Thursday, December 29, 2022SOU EXTENSION 2 FILED
Thursday, December 29, 2022SOU EXTENSION 2 GRANTED
Saturday, December 31, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 29, 2023SOU TEAS EXTENSION RECEIVED
Thursday, June 29, 2023SOU EXTENSION 3 FILED
Thursday, June 29, 2023SOU EXTENSION 3 GRANTED
Saturday, July 1, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 20, 2023SOU EXTENSION 4 FILED
Wednesday, December 20, 2023SOU EXTENSION 4 GRANTED
Wednesday, December 20, 2023SOU TEAS EXTENSION RECEIVED
Friday, July 5, 2024SOU TEAS EXTENSION RECEIVED
Friday, July 5, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, July 5, 2024SOU EXTENSION 5 FILED
Friday, July 5, 2024SOU EXTENSION 5 GRANTED
Friday, December 22, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

rakynvis diseases disorders oncological treatment preparations pharmaceutical